Download MendeleySmall molecule targeting of transcription-replication conflict for selective chemotherapy.
Gu, L., Li, M., Li, C.M., Haratipour, P., Lingeman, R., Jossart, J., Gutova, M., Flores, L., Hyde, C., Kenjic, N., Li, H., Chung, V., Li, H., Lomenick, B., Von Hoff, D.D., Synold, T.W., Aboody, K.S., Liu, Y., Horne, D., Hickey, R.J., Perry, J.J.P., Malkas, L.H.(2023) Cell Chem Biol 30: 1235
- PubMed: 37531956
- DOI: https://doi.org/10.1016/j.chembiol.2023.07.001
- Primary Citation of Related Structures:
8GL9, 8GLA - PubMed Abstract:
Targeting transcription replication conflicts, a major source of endogenous DNA double-stranded breaks and genomic instability could have important anticancer therapeutic implications. Proliferating cell nuclear antigen (PCNA) is critical to DNA replication and repair processes. Through a rational drug design approach, we identified a small molecule PCNA inhibitor, AOH1996, which selectively kills cancer cells. AOH1996 enhances the interaction between PCNA and the largest subunit of RNA polymerase II, RPB1, and dissociates PCNA from actively transcribed chromatin regions, while inducing DNA double-stranded breaks in a transcription-dependent manner. Attenuation of RPB1 interaction with PCNA, by a point mutation in RPB1's PCNA-binding region, confers resistance to AOH1996. Orally administrable and metabolically stable, AOH1996 suppresses tumor growth as a monotherapy or as a combination treatment but causes no discernable side effects. Inhibitors of transcription replication conflict resolution may provide a new and unique therapeutic avenue for exploiting this cancer-selective vulnerability.
Organizational Affiliation:
Department of Molecular Diagnostics & Experimental Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA, USA. Electronic address: Lgu@coh.org.
